What is the recommended management for a 22‑year‑old man with anxiety and depression who is well controlled on sertraline 50 mg daily but reports occasional emotional blunting?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Emotional Blunting on Sertraline

For this 22-year-old with well-controlled depression and anxiety on sertraline 50 mg but experiencing emotional blunting, augment with bupropion SR rather than switching medications, as this preserves the established therapeutic benefit while addressing the emotional numbing. 1

Rationale for Augmentation Over Switching

The patient has achieved good symptom control—a critical therapeutic milestone that should not be abandoned lightly. The 2023 American College of Physicians guideline demonstrates that augmentation strategies (adding bupropion SR to existing SSRI therapy) show similar efficacy to switching strategies, but importantly, augmentation preserves the gains already made 1. In the STAR*D trial analysis, augmentation with bupropion SR had significantly lower discontinuation rates due to adverse events (12.5%) compared to buspirone augmentation (20.6%), and fewer adverse events than cognitive therapy augmentation 1.

Why Bupropion Specifically

  • Mechanism: Bupropion works through norepinephrine-dopamine reuptake inhibition, a completely different mechanism than sertraline's serotonergic action, which may counteract the emotional blunting
  • Evidence: Research shows emotional blunting appears less frequent with bupropion compared to other antidepressants 2, and bupropion had the lowest rate of emotional blunting (31.82%) among antidepressants studied 3
  • Safety profile: The STAR*D data specifically supports bupropion SR augmentation with lower adverse event discontinuation rates 1

Clinical Context of Emotional Blunting

Emotional blunting affects 40-60% of patients on SSRIs 3, and approximately 46% of depressed patients on antidepressants report this phenomenon 2. Critically, nearly 40% of patients consider stopping their antidepressant due to emotional numbing 3, making this a quality-of-life issue that threatens treatment adherence and long-term outcomes.

The current sertraline dose of 50 mg is at the lower end of the therapeutic range (50-200 mg/day per FDA labeling) 4, but dose escalation is not recommended here because research shows adverse effects, including emotional blunting, may increase at doses above 150 mg 5, and emotional blunting appears common across all monoaminergic antidepressants regardless of dose 2.

Implementation Algorithm

  1. Add bupropion SR starting at 150 mg daily, which can be increased to 300 mg daily if needed
  2. Continue sertraline 50 mg unchanged—do not taper or adjust
  3. Reassess at 2-4 weeks for improvement in emotional range while monitoring for:
    • Maintained depression/anxiety control
    • Any activation symptoms (agitation, insomnia)
    • Seizure risk factors (bupropion contraindication)

Alternative if Augmentation Fails

If augmentation with bupropion does not resolve emotional blunting after adequate trial (4-6 weeks), then consider switching from sertraline to bupropion monotherapy or to mirtazapine. The guideline evidence shows no difference in efficacy or safety between switching strategies versus augmentation strategies when comparing sertraline-to-mirtazapine switch versus sertraline-plus-mirtazapine augmentation 1.

Common Pitfalls to Avoid

  • Don't dismiss the complaint: Emotional blunting correlates with poorer quality of remission and is a legitimate treatment-limiting side effect 2
  • Don't simply increase sertraline dose: This won't address the mechanism causing emotional blunting and may worsen it
  • Don't switch prematurely: The patient has achieved good control; preserve this by augmenting first
  • Don't confuse with residual depression: The patient reports good depression/anxiety control, distinguishing this from inadequate treatment response

References

Related Questions

Can bupropion (Wellbutrin) cause emotional blunting or make some patients feel emotionless?
In a patient taking duloxetine 30 mg daily who reports emotional blunting but no sexual side effects, how should the treatment be adjusted?
A 13-year-old patient has been taking sertraline 75 mg daily for four weeks and now reports emotional blunting and numbness; what should be the next management step?
What antidepressants are most likely to cause minimal affective blunting in an adult patient without known contraindications?
Should I increase my sertralina (sertraline) dose from 50mg to manage my recurring depressive symptoms, given my history of anxiety and depression?
In a 55‑year‑old woman with generalized anxiety disorder and a current severe mixed bipolar episode with psychotic features who is taking trazodone 100 mg at bedtime, lamotrigine (Lamictal) 100 mg twice daily, hydroxyzine 25 mg every six hours as needed (to be discontinued tomorrow), and quetiapine 50 mg twice daily, which buspirone dosing regimen—5 mg twice daily, 5 mg three times daily, or 10 mg twice daily—is most appropriate for her high anxiety?
How should I manage a patient with cerebral dural sinus thrombosis who is currently on Xeralto (rivaroxaban), including appropriate dosing, monitoring, and alternatives if contraindicated?
Can imaging alone be sufficient to diagnose inflammatory bowel disease?
What are the recommended medication treatments for bipolar II disorder with a depressive episode and psychotic features?
Is it safe for a patient with glaucoma to initiate hormone replacement therapy (HRT)?
Which antinuclear antibody test should be ordered, the indirect immunofluorescence assay on HEp‑2 cells (IFA) or the ELISA screening?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.